RIPK1 is becoming a relative desert for large drugmakers. Eli Lilly has joined the exodus, ripping apart the remainder of its up to $960 million

The FDA has extended its review of a new version of Sanofi’s multiple myeloma Sarclisa that could help narrow the gap with arch-rival Darzalex.

Roche remains confident in the prospects for its soon-to-be-filed oral BTK drug fenebrutinib for multiple sclerosis, despite safety concerns.

The first volunteers in a large-scale trial of Moderna’s mRNA-based vaccine against bird flu have received shots in the UK and US.

Medicare will cover the cost of a pilot of weight-loss drug coverage, after health insurers refuse to take part.